BICO, an expert company for bioconvergence, has been granted two patents regarding regulation and control of temperatures in 3D Bioprinters. The first patent, US 11,046,001, was granted in the USA and relates to temperature control of biolinks which enables better cell viability under 3D bioprints. The second patent, SE 543880, was granted in Sweden and relates to control of the temperature of the discharge nozzle under the 3D bioprint, which leads to increased print consistency, less downtime due to clogging and less material waste.
“Our mission at BICO is to create the future of medicine and improve health globally through convergence between key biotechnologists.” Explained Erik Gatenholm, CEO and founder of BICO. “This innovation will help our incredible customers drive advances in drug discovery, tissue engineering and disease modeling.”
BICO believes that 3D bioprinting will accelerate drug development and eventually alleviate the burden on organ transplants, and this patent is an important milestone in that mission. It is important during the printing process to maintain a constant temperature to keep the cells alive at 37 degrees Celsius. Temperature control is also very useful when using biolinks such as Gelma and Collagen to avoid clogging needles and nozzles. The two patents strengthen the company’s protection of intellectual property rights and complement a complete portfolio of solutions developed by BICO and its subsidiary CELLINK.
“At BICO, we work tirelessly to consistently improve and renew our bioprint printing offerings,” says Dr. Héctor Martínez, co-founder and Chief Technology Officer at BICO. “Our customers around the world are constantly pushing the boundaries of science with our technology and I’m excited to see how they use these innovations to make the world a healthier place.”
3D bioprinting is an important tool for the production of soft materials, tissue models and 3D cell culture environments. As the global leader in 3D bioprinting, BICO and CELLINK have developed cutting-edge biofabrication technologies, including extrusion-based bioprinters, light-based bioprinters, living cell image cells, inks and accessories. The company’s products are found in more than 2,000 of the world’s most innovative laboratories including Stanford, Harvard, Merck, Novartis, AstraZeneca, Johnson & Johnson and others.